Short course of treatment with RNS60 extends survival in ALS
A short course of treatment with Revalesio‘s RNS60 as an add-on to standard amyotrophic…
Articles by Patricia Inácio, PhD
RAG-17 safe, shows early signs of efficacy as SOD1-ALS treatment
RAG-17, an investigational therapy from Ractigen Therapeutics, was safe and well tolerated across all tested doses in people with…
NRG Therapeutics gets grant to test mitochondria-targeting ALS therapy
NRG Therapeutics has received a grant from the nonprofit Target ALS to advance preclinical studies of its new…
2 proteins identified as potential therapeutic targets in FUS-ALS
Targeting two particular proteins, called H1.2 and PARP1, may lessen the severity of amyotrophic lateral sclerosis (ALS) linked to mutations…
Over 420 ‘Fill the Boot’ events in US to raise funds for MDA
The Muscular Dystrophy Association (MDA) and the International Association of Fire Fighters (IAFF) are teaming up once again, launching more…
First group of healthy volunteers enrolled in ATH-1105 study
Athira Pharma has completed enrollment of the first group of healthy volunteers who’ll receive a single dose of ATH-1105…
Patient enrollment now complete in DNL343 arm of HEALEY ALS trial
Patient enrollment is now complete in an arm of the HEALEY ALS platform trial that’s testing Denali…
PhD student wins 2024 Illinois Innovation Award for work in ALS
Alejandra Zeballos, a PhD student in bioengineering at the University of Illinois Urbana-Champaign, was awarded the 2024…
PrimeC significantly slows ALS progression in certain trial patients
PrimeC, a treatment candidate for amyotrophic lateral sclerosis (ALS), was found to significantly slow disease progression in certain…
ASHA-624 to be studied as potential disease-modifying therapy
ASHA-624, an experimental therapy that blocks the activity of the SARM1 protein, will be developed as a potential disease-modifying therapy…